SecBot SecBot

CGTX

COGNITION THERAPEUTICS INC
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001455365 Biotech & Drug Discovery
$0.7262 +0.01 (+1.00%)
Oct 26 4:00 PM ET · prev $0.7190
Market cap
$66.6M
Micro cap
Median target
$3.00
+313% · range $3.00–4.00
Next earnings
Nov 18
in 23 days · EPS est. −$0.07
1 year
−56.8%
from $1.68 · Oct 27
30 days
−22.6%
from $0.9380
52-week range
$0.5950–1.80
−60% from high · low Mar 30
Avg volume 20D
619.1K
Oct 13 spike 3.76M
Short interest
7.58M
≈8.0% of shares · −2.1%
Days to cover
16.6
at average volume
Insider net
+$32.5K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Cognition Therapeutics announced FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $32.5K at an average $1.11. No open-market sales. Price is 35% below their cost.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 3 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.072 → −$0.067 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −2.1% to 7.58M shares. 16.6 days to cover, ≈8.0% of shares.

  • TrendDOWNTREND

    22% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
DAVENPORT & Co LLCADD4,259,511$4.9M
BlackRock, Inc.ADD1,261,993$1.5M
RENAISSANCE TECHNOLOGIES LLCTRIM693,288$797.3K
UBS Group AGDOUBLED218,536$251.3K
Creative PlanningTRIM22,200$25.5K
Cetera Investment AdvisersTRIM19,850$22.8K
OSAIC HOLDINGS, INC.ADD4,200$4.8K
JANE STREET GROUP, LLCTRIM370,140$281.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +313%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Mar 27, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Dec 4, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 21, 2025B. Riley Securities
REITERATE
REITERATEBuy
Nov 19, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 8, 2025Chardan Capital
MAINTAIN
MAINTAINBuy
Jun 26, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$32.5K
bought · 3 insiders
$0
sold · 0 insiders
−34.8%
vs their $1.11 cost
DateInsiderTypeValue
Jun 17, 2026
Fletcher Aaron G.L.
Director
AWARD25,000 sh
Jun 17, 2026
RICHSTONE ELLEN B
Director
AWARD25,000 sh
Jun 17, 2026
Wallace Peggy
Director
AWARD25,000 sh
Jun 17, 2026
Monia Brett P
Director
AWARD25,000 sh
Jun 17, 2026
Khattar Jack A.
Director
AWARD25,000 sh
May 1, 2026
Doyle John Brendan
Chief Financial Officer
TAX W/H$11.0K
Apr 16, 2026
Doyle John Brendan
Chief Financial Officer
BUY$11.3K
Apr 16, 2026
Caggiano Anthony
Chief Medical Officer
BUY$11.1K

Earnings setup

Estimates
Nov 18
reports in 23 days
−$0.07
EPS estimate, this quarter
+8%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.07-$0.07–-$0.06+0.0%$0.00
Next Q-$0.14-$0.26–-$0.05+0.0%$0.00
Current FY-$0.30-$0.42–-$0.20+0.0%$0.00
Next FY-$0.22-$0.25–-$0.19+0.0%$0.00

Short side

FINRA· Sep 30, 2026
7,579,141
shares short
-2.1%
vs prior settlement
16.6
days to cover
≈8.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Cognition Therapeutics announced FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine (CT1812) in…
8-K — Impact 7/10
Sep 8, 2026 Other
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a cl
Jun 30, 2026 Inst.
DAVENPORT & Co LLC — ADD
4,259,511 shares ($4.9M)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
1,261,993 shares ($1.5M)
Jun 17, 2026 Insider
Fletcher Aaron G.L. was granted 25,000 shares
Director
Jun 17, 2026 Insider
RICHSTONE ELLEN B was granted 25,000 shares
Director
Jun 17, 2026 Insider
Wallace Peggy was granted 25,000 shares
Director
Jun 4, 2026 SEC
Cognition Therapeutics filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare…
8-K — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
CGTX Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Sep 8, 2026
Press release
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat…
Aug 14, 2026
Short interest
Short Interest: CGTX down 20% to 7.1M shares
Settlement 2026-08-14 | Days to cover: 10.05 | ≈7.49% of shares outstanding (est.)
Aug 11, 2026
Earnings date
CGTX Q2 2026 Earnings Scheduled — 2026-08-11
Aug 5, 2026
Earnings date
CGTX Q2 2026 Earnings Scheduled — 2026-08-05
Jul 15, 2026
Short interest
Short Interest: CGTX up 37% to 9.7M shares
Settlement 2026-07-15 | Days to cover: 4.81 | ≈10.81% of shares outstanding (est.)

SecBot reports

4 filings · 7 press releases · 2 bullish · 0 bearish · 2 neutral
All CGTX filing & press-release reports (11)